S1P/S1P Receptor Pathway: A New Target for Treatment of Inflammatory Bowel Disease
10.3969/j.issn.1008-7125.2023.01.012
- Author:
Kehui ZHANG
1
;
Yong LI
1
Author Information
1. Department of Gastroenterology, Shanghai Municipal Hospital of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
Immunomodulation;
Inflammatory Bowel Disease;
Intestinal Microbiota;
Lymphocyte Homing;
S1P/S1P Receptors;
Therapy
- From:
Chinese Journal of Gastroenterology
2023;28(1):57-61
- CountryChina
- Language:Chinese
-
Abstract:
The development of targeted oral drugs that can stably treat inflammatory bowel disease (IBD) is still a clinical problem to be solved. In recent years, studies have confirmed that sphingosine⁃1⁃phosphate (S1P)/S1P receptor pathway can regulate lymphocyte homing and immune regulation, inhibit intestinal inflammation, protect intestinal endothelial barrier, and affect intestinal microbial metabolism, which may play a key role in the treatment of IBD. This article reviewed the effect of S1P/S1P receptor pathway on IBD and its potential mechanism.
